Home/Pipeline/Lu AG13909

Lu AG13909

Schizophrenia

Phase 1Active

Key Facts

Indication

Schizophrenia

Phase

Phase 1

Status

Active

Company

Lundbeck

About Lundbeck

Lundbeck is a Danish, publicly-traded biopharmaceutical leader with a century-long legacy, exclusively focused on central nervous system (CNS) disorders. Its strategy as a 'Focused Innovator' leverages deep, accumulated expertise in neuroscience to navigate the complexities of CNS drug development and commercialization. The company has built a significant global commercial footprint, particularly in the U.S., and maintains a robust pipeline aimed at addressing high-unmet-need conditions in psychiatry, neurology, and neuro-rare diseases, underpinned by a strong financial position with a market valuation of approximately $39 billion.

View full company profile

Therapeutic Areas

Psychiatry Neurology Neuro-rare Diseases

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Olanzapine LAI (TEV-‘749)	Teva	Phase 3	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active
Risperidone Implant	Delpor	Phase 1b/2a / Late-stage	Active
Preclinical Kv3 Modulators	Autifony Therapeutics	Preclinical	Active